All In Biotech

Drug Trial Radar · NCT06195072

Platform Clinical Study for Conquering Scleroderma

Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants With Interstitial Lung Disease Secondary to Systemic Sclerosis

Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Apr 15, 2024

Primary completion

Nov 2026

Study completion Nov 2026

Sponsor

Lead sponsor
Scleroderma Research Foundation, Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sanofi; Boehringer Ingelheim
First posted
Jan 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.

Conditions

  • Interstitial Lung Disease Due to Systemic Disease
  • Scleroderma

Interventions

  • AmlitelimabDrug

    IP will be administered subcutaneously by the Investigator or designee as follows: * Amlitelimab or * Matching placebo

  • BI 1015550 (Nerandomilast)Drug

    Study participants will take the active investigational product BI 1015550 (Nerandomilast) or matching placebo provided as film-coated tablets, administered orally BID.

  • PlaceboDrug

    see Experimental Arm intervention description

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in forced vital capacity (FVC, in mL).Time frame: from baseline to the end of the treatment period at Week 52

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama - Division of Pulmonary and Critical Care Medicine

    Birmingham, Alabama · Recruiting

  • Keck School of Medicine at USC Medical Center

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • University of California, Los Angeles (UCLA) Ronald Reagan Medical Center

    Los Angeles, California · Withdrawn

  • Stanford University Medical Center

    Palo Alto, California · Recruiting

  • Yale University School of Medicine - Epilepsy

    New Haven, Connecticut · Withdrawn

  • Georgetown University Medical Center - Department of Rheumatology

    Washington D.C., District of Columbia · Recruiting

  • Emory University School of Medicine

    Atlanta, Georgia · Withdrawn

  • Northwestern University

    Chicago, Illinois · Completed

  • The University of Chicago Medical Center (UCMC)

    Chicago, Illinois · Recruiting

  • University of Kansas School of Medicine

    Kansas City, Kansas · Recruiting

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Boston University (BU)

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Withdrawn

  • Robert Wood Johnson Medical School

    New Brunswick, New Jersey · Recruiting

  • Northwell Health

    Great Neck, New York · Recruiting

  • Hospital for Special Surgery

    New York, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Withdrawn

  • Oregon Health & Science University (OHSU)

    Portland, Oregon · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania · Recruiting

  • Temple University Hospital

    Philadelphia, Pennsylvania · Withdrawn

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Withdrawn

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina · Recruiting

  • Meharry Medical College

    Nashville, Tennessee · Withdrawn

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Not yet recruiting

  • University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics

    Houston, Texas · Recruiting

  • The University of Utah Health Sciences Center

    Salt Lake City, Utah · Withdrawn

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.